{
  "ticker": "LLY",
  "target_date": "2025-04-15",
  "actual_date": "2025-04-15",
  "collected_at": "2025-12-08T11:38:38.796993",
  "price": {
    "open": 751.27,
    "high": 760.95,
    "low": 747.21,
    "close": 752.8694458007812,
    "volume": 2458100,
    "change_1d_pct": 0.38,
    "change_7d_pct": 2.57,
    "change_30d_pct": -16.89
  },
  "technicals": {
    "rsi_14": 35.29,
    "sma_20": 788.01,
    "sma_50": 832.52,
    "macd": -27.96,
    "macd_signal": -24.504,
    "macd_histogram": -3.456,
    "bb_upper": 885.04,
    "bb_lower": 690.99,
    "price_vs_sma20_pct": -4.46,
    "price_vs_sma50_pct": -9.57,
    "volume_ratio": 0.66
  },
  "fundamentals": {
    "market_cap": 889332170752,
    "pe_ratio": 48.606197,
    "forward_pe": 43.7799,
    "price_to_book": 37.351376,
    "price_to_sales": 14.966933,
    "profit_margin": 30.99,
    "operating_margin": 48.29,
    "roe": 96.47,
    "roa": 17.6,
    "revenue_growth": 53.9,
    "earnings_growth": 480.4,
    "debt_to_equity": 178.516,
    "current_ratio": 1.546,
    "quick_ratio": 0.724,
    "dividend_yield": 59.0,
    "fifty_two_week_high": 1111.99,
    "fifty_two_week_low": 623.78,
    "fifty_day_avg": 911.5326,
    "two_hundred_day_avg": 811.9354,
    "analyst_target": 1056.7045,
    "analyst_recommendation": "buy",
    "num_analysts": 27,
    "sector": "Healthcare",
    "industry": "Drug Manufacturers - General",
    "pct_from_52w_high": -10.79,
    "pct_from_52w_low": 59.04
  },
  "macro": {
    "spy": {
      "price": 534.54,
      "change_1d_pct": -0.28,
      "change_7d_pct": 6.59
    },
    "vix": {
      "level": 30.12,
      "signal": "HIGH_FEAR"
    },
    "treasury_10y": {
      "yield_pct": 4.32
    },
    "dollar_index": {
      "level": 100.22
    },
    "gold": {
      "price": 3218.7
    },
    "regime": "SIDEWAYS"
  },
  "news": [
    {
      "headline": "Eli Lilly (LLY) Gains As Market Dips: What You Should Know",
      "source": "Yahoo",
      "datetime": 1744753516,
      "summary": "In the most recent trading session, Eli Lilly (LLY) closed at $757.18, indicating a +0.38% shift from the previous trading day.",
      "url": "https://finnhub.io/api/news?id=aa3f7c261f763e1dfa95ba349aad86c0ab18ab35fdb97093ebba4523b1f45ce7"
    },
    {
      "headline": "Is Eli Lilly and Company (LLY) the Best Pharma Stock to Buy for Long Term Growth?",
      "source": "Yahoo",
      "datetime": 1744738597,
      "summary": "We recently published a list of 10 Best Pharma Stocks to Buy for Long Term Growth. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against other best pharma stocks to buy for long term growth. U.S. Pharma Turns to China for Drug Deals With big [\u2026]",
      "url": "https://finnhub.io/api/news?id=b6ff35210685ab0541e607e1b08b32dd0cc4e43c1ebbfd09d3d88c626e82b7aa"
    },
    {
      "headline": "Pfizer Halts Obesity Pill Development Amid Safety Concerns",
      "source": "Yahoo",
      "datetime": 1744736220,
      "summary": "PFE's decision to scrap the development of danuglipron comes after a study participant develops potential drug-induced liver injury.",
      "url": "https://finnhub.io/api/news?id=3331affb6c0b2bf193e2d253ab1303d26d95a032425f678a2e113d4054063d46"
    },
    {
      "headline": "VERV Stock Soars on Superior Efficacy in Phase I Cholesterol Study",
      "source": "Yahoo",
      "datetime": 1744734420,
      "summary": "Verve Therapeutics stock rises on demonstrating superior LDL-C lowering ability in a phase Ib study of VERVE-102 in patients with HeFH and/or CAD.",
      "url": "https://finnhub.io/api/news?id=ba34d0e9e01b07024fe08b6cafea6fe346d4125ef3d9e36cc27f83c70f82bfab"
    },
    {
      "headline": "Viking Therapeutics: Trading The Volatility Of The Weight Loss Drug Market",
      "source": "SeekingAlpha",
      "datetime": 1744734098,
      "summary": "Viking Therapeutics, Inc.'s VK2735 has potential as a GLP-1 for obesity amid Pfizer's exit, but competition and financing risks remain. Click to know why VKTX is a Buy.",
      "url": "https://finnhub.io/api/news?id=f66e70cb2ce25d77f2724f8f6197654f1de5fe206e0af337fb60130dcbccc506"
    }
  ],
  "news_count": 5,
  "sec_filings": [
    {
      "form": "4",
      "date": "2025-03-19",
      "description": "xslF345X05/wk-form4_1742416067.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947825000103/xslF345X05/wk-form4_1742416067.xml"
    },
    {
      "form": "4",
      "date": "2025-03-19",
      "description": "xslF345X05/wk-form4_1742415936.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947825000101/xslF345X05/wk-form4_1742415936.xml"
    },
    {
      "form": "4",
      "date": "2025-03-19",
      "description": "xslF345X05/wk-form4_1742415842.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947825000099/xslF345X05/wk-form4_1742415842.xml"
    },
    {
      "form": "4",
      "date": "2025-03-19",
      "description": "xslF345X05/wk-form4_1742415665.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947825000097/xslF345X05/wk-form4_1742415665.xml"
    },
    {
      "form": "4",
      "date": "2025-03-19",
      "description": "xslF345X05/wk-form4_1742415462.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947825000095/xslF345X05/wk-form4_1742415462.xml"
    }
  ],
  "sec_filings_count": 5,
  "data_quality": {
    "has_price": true,
    "has_technicals": true,
    "has_fundamentals": true,
    "has_macro": true,
    "has_news": true,
    "has_sec_filings": true
  }
}